The Company

Eurocine Vaccines has attracted internationally recognized experts to quest for the vaccines of tomorrow. Specialized in vaccine development, and with decades long experience, the highly qualified team has a proven record to manage all aspects of vaccine development including preclinical and clinical development, scalability into production, as well as business development and financing.

Today a publicly listed company situated close to the Karolinska Institutet, home of the Nobel Assembly.​

Read our story =>
Get to know our candidates =>
Learn more how we bridge the gap between innovation and market =>
For investors =>

Organisation

Team

CEO and Board Director

Dr. Hans Arwidsson

Dr. Hans Arwidsson is a former Air Force pilot with more than three decades of broad cross-functional executive experience from the pharmaceutical industry. Both from Big Pharma as AstraZeneca, and from several independent entrepreneurial companies, before joining Eurocine Vaccines. He holds a M.Sc. and a Ph.D. in pharmaceutical sciences from Uppsala University as well as an Executive MBA from Stockholm School of Economics.

Director of CMC Development

Ms. Sandra Jeldes Granstrand

Sandra Jeldes Granstrand enjoys a movie or to make pottery when not busy ensuring well controlled manufacturing and quality of our vaccine products, i.e. Chemistry Manufacturing and Control. She graduated as a Master of Engineering at the Royal Institute of Technology in Stockholm, specialized in Bio-Medical Technology. Previously Deputy Head of Laboratory and CMC at Newron.

Director of Preclinical Development

Dr. Karl Ljungberg

Dr. Karl Ljungberg runs an art museum together with his family and has extensive experience of immunology, virology and particularly vaccinology from Karolinska Institutet, University of North Carolina and Public Health Agency of Sweden. He holds a M.Sc. in Molecular Biology from Stockholm University and a Ph.D. in Infectious Disease Control from Karolinska Institutet.

Project Leader CMC Development

Dr. Stephen Toddo

Dr. Stephen Toddo’s curiosity for biology begun with a passion for training and interest in the human body. After leaving his career as a Personal Trainer he graduated in neurochemistry, with specialization on molecular neurobiology followed by a Ph.D. where he specialized in protein production, focusing in expression of difficult-to-express proteins. Prior joining Eurocine Vaccines he worked with development of manufacturing procedures and purification processes at SOBI.

Board

Chairman of the Board

Dr. Pierre A. Morgon

Today, Dr Morgon is a well acknowledged name with over 30 years of experience in the global pharmaceutical and biological industry. He has previously served at senior positions at e.g. ICI-Pharma, Synthelabo, Yamanouchi Pharma, BMS, Drug Abuse Sciences, Bio Alliance Pharma , Schering-Plough and Aventis Sanofi Pasteur. Today, a CEO, Chairman, Non-Executive Director and Advisor for a multitude of companies within the vaccine industry, as well as Regional Partner of Merieux Develeppement. Pierre A. Morgon holds a Doctorate of Pharmacy, a Master in Business Law and a MBA.

Non-Executive Director of the Board

Mr. Jan Sandström​

Jan Sandström has a long career and extensive experience from the pharmaceutical industry as Business Developer and Board Member including Astrazeneca, PledPharma and TikoMed. He holds a M.Sc. in Pharmaceutical Sciences and a degree in Business Administration, and has previously participated in the development of the Swedish Shareholders’ Association as its Board Member.

Non-Executive Director of the Board

Mr. Pär Thuresson

With a proven record as entrepreneur and businessman, Mr Thuresson is today the CEO and Board Director of the Industry Group Thuresson Sweden AB and a non-executive Director in several other companies.

Non-Executive Director of the Board

Prof. Emanuele Montomoli

Emanuele Montomoli is a highly respected professor of Public Health in the Department of Molecular Medicine at the University of Siena. Engaged deeply in the vaccine industry, he is also the founder of VisMederi, a research laboratory offering services for clinical studies of human infectious diseases. He is currently participating in two EU-funded projects that are developing new methods to evaluate vaccines and their adjuvants. He is a board member of the ISIRV and has published nearly 70 scientific articles and several chapters in scientific textbooks in the field.

President, CEO and Board Director

Dr. Hans Arwidsson

Please see Team above.